An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Predictive Oncology Inc. (NASDAQ: POAI) announces that an abstract has been accepted for presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The abstract showcases the results of a study on predicting survival outcomes in ovarian cancer using AI-driven models, in collaboration with UPMC Magee-Womens Hospital.
Predictive Oncology Inc. (NASDAQ: POAI) annuncia che un abstract è stato accettato per la presentazione all'incontro annuale 2024 della American Society of Clinical Oncology (ASCO). L'abstract presenta i risultati di uno studio sulla previsione degli esiti di sopravvivenza nel cancro ovarico utilizzando modelli basati sull'intelligenza artificiale, in collaborazione con l'UPMC Magee-Womens Hospital.
Predictive Oncology Inc. (NASDAQ: POAI) anuncia que un resumen ha sido aceptado para presentación en la Reunión Anual de 2024 de la Sociedad Americana de Oncología Clínica (ASCO). El resumen muestra los resultados de un estudio sobre la predicción de los resultados de supervivencia en cáncer de ovario utilizando modelos impulsados por IA, en colaboración con el Hospital Magee-Womens de UPMC.
Predictive Oncology Inc. (NASDAQ: POAI)는 2024년 미국 임상 종양학회(ASCO) 연례 회의에서 초록이 발표될 예정임을 발표했습니다. 이 초록은 UPMC Magee-Womens 병원과 협력하여 인공 지능 기반 모델을 사용하여 난소암의 생존 결과를 예측하는 연구 결과를 보여줍니다.
Predictive Oncology Inc. (NASDAQ: POAI) annonce qu'un résumé a été accepté pour une présentation à la réunion annuelle 2024 de la Société Américaine d'Oncologie Clinique (ASCO). Le résumé expose les résultats d'une étude sur la prédiction des issues de survie dans le cancer de l'ovaire utilisant des modèles pilotés par IA, en collaboration avec l'hôpital UPMC Magee-Womens.
Predictive Oncology Inc. (NASDAQ: POAI) gibt bekannt, dass ein Abstract für die Präsentation auf der Jahrestagung 2024 der American Society of Clinical Oncology (ASCO) akzeptiert wurde. Das Abstract zeigt die Ergebnisse einer Studie zur Vorhersage der Überlebensergebnisse bei Eierstockkrebs unter Verwendung von KI-gesteuerten Modellen, in Zusammenarbeit mit dem UPMC Magee-Womens Hospital.
Positive
None.
Negative
None.
PITTSBURGH, April 24, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, today announced that an abstract has been accepted for presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, which is being held May 31-June 4, 2024, in Chicago, Il.
The abstract highlights results from a recent study that Predictive Oncology completed in collaboration with UPMC Magee-Womens Hospital in Pittsburgh, PA. The study utilized multi-omic machine learning models to determine if they could better predict short- and long-term survival outcomes among women diagnosed with high grade serous ovarian cancer (HGSC) as compared to clinical data alone.
Title:
Using Artificial Intelligence-Powered Evidence-Based Molecular Decision-Making for Improved Outcomes in Ovarian Cancer
Abstract #:
5555
Poster bd#:
426
Session:
Gynecologic Cancer
Date/time:
Monday, June 3rd, 9:00am – 12:00pm CDT (10:00am-1:00pm EDT)
Presenter:
Brian Christopher Orr, MD, MS, Gynecologic Oncologist at the Hollings Cancer Center and assistant professor at the Medical University of South Carolina
The full abstract will be available on meetings.asco.org on May 23rd at 5:00 PM ET.
About Predictive Oncology Predictive Oncology is on the cutting edge of the rapidly growing use of artificial intelligence and machine learning to expedite early drug discovery and enable drug development for the benefit of cancer patients worldwide. The company’s scientifically validated AI platform, PEDAL, is able to predict with 92% accuracy if a tumor sample will respond to a certain drug compound, allowing for a more informed selection of drug/tumor type combinations for subsequent in-vitro testing. Together with the company’s vast biobank of more than 150,000 assay-capable heterogenous human tumor samples, Predictive Oncology offers its academic and industry partners one of the industry’s broadest AI-based drug discovery solutions, further complimented by its wholly owned CLIA lab and GMP facilities. Predictive Oncology is headquartered in Pittsburgh, PA.
Forward-Looking Statements: Certain matters discussed in this release contain forward-looking statements. These forward- looking statements reflect our current expectations and projections about future events and are subject to substantial risks, uncertainties and assumptions about our operations and the investments we make. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenue and financial performance, projected costs, prospects, changes in management, plans and objectives of management are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “would,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our actual future performance may materially differ from that contemplated by the forward-looking statements as a result of a variety of factors including, among other things, factors discussed under the heading “Risk Factors” in our filings with the SEC. Except as expressly required by law, the Company disclaims any intent or obligation to update these forward-looking statements.
FAQ
What event did Predictive Oncology announce participation in?
Predictive Oncology announced that an abstract has been accepted for presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
Where and when will the ASCO Annual Meeting take place?
The ASCO Annual Meeting will be held in Chicago, IL, from May 31 to June 4, 2024.
What is the focus of the abstract accepted by Predictive Oncology?
The abstract focuses on using AI-driven models to predict short- and long-term survival outcomes in women diagnosed with high grade serous ovarian cancer (HGSC).
Who collaborated with Predictive Oncology on the study mentioned in the abstract?
Predictive Oncology collaborated with UPMC Magee-Womens Hospital in Pittsburgh, PA, on the study.
When will the full abstract be available for viewing?
The full abstract will be available on meetings.asco.org on May 23rd at 5:00 PM ET.
predictive oncology (nasdaq: poai) is focused on the use of data and artificial intelligence (ai) to develop personalized cancer therapies, which can lead to more effective treatments and improved patient outcome. the company has several tools that support its mission of bringing precision medicine to the diagnosis of cancer. through its subsidiaries, predictive oncology’s portfolio of assets includes the following: - a database of clinically validated historical and outcome data from patient tumors - an in-house clinical laboratory improvement amendments (clia)-certified lab - a “smart” patient-derived tumor profiling platform - an in-house bioinformatics artificial intelligence (ai) platform - a new computerized approach growing tumors in the lab to rapidly develop patient specific treatment options - an fda-approved fluid collection and disposal system using these resources, and in collaboration with key players in the pharmaceutical, diagnostic and biotech industries
